Use of anastrozole for breast cancer prevention (IBIS-II): long-term results of a randomised controlled trial.

ABSTRACT:

Background

Two large clinical trials have shown a reduced rate of breast cancer development in high-risk women in the initial 5 years of follow-up after use of aromatase inhibitors (MAP.3 and International Breast Cancer Intervention Study II [IBIS-II]). Here, we report blinded long-term follow-up results for the IBIS-II trial, which compared anastrozole with placebo, with the objective of determining the efficacy of anastrozole for preventing breast cancer (both invasive and ductal carcinoma in situ) in the post-treatment period.

Methods

IBIS-II is an international, randomised, double-blind, placebo-controlled trial. Postmenopausal women at increased risk of developing breast cancer were recruited and were randomly assigned (1:1) to either anastrozole (1 mg per day, oral) or

SUBMITTER: Cuzick J 

PROVIDER: S-EPMC6961114 | biostudies-literature | 2020 Jan

REPOSITORIES: biostudies-literature